{"id":911529,"date":"2025-11-19T08:07:01","date_gmt":"2025-11-19T13:07:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/"},"modified":"2025-11-19T08:07:01","modified_gmt":"2025-11-19T13:07:01","slug":"join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/","title":{"rendered":"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9"},"content":{"rendered":"
\n

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET.<\/p>\n

The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie\u2019s first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer\u2019s, Parkinson\u2019s, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation across clinical studies. He will also outline progress with BIV201, BioVie\u2019s late-stage orphan drug candidate for refractory ascites, a life-threatening complication of liver cirrhosis with no FDA-approved therapies. With multiple late-stage clinical programs advancing, strong safety data, and multi-billion-dollar market opportunities, BioVie is positioned to deliver significant value creation as it approaches pivotal milestones and potential partnerships.<\/p>\n

A live Q&A session with management will follow the presentation.<\/p>\n

To register for the free webinar, please visit: https:\/\/www.redchip.com\/webinar\/BIVI\/87918761553<\/a><\/p>\n

Questions can be pre-submitted to BIVI@redchip.com<\/a> or online during the live event.<\/p>\n

\n About BioVie, Inc.<\/strong>\n <\/p>\n

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer\u2019s disease, Parkinson\u2019s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company\u2019s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-\u03baB, and the associated neuroinflammation and insulin resistance but not ERK and NF\u03baB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company\u2019s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit\u00a0www.bioviepharma.com<\/a>. \u00a0<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.\u00a0\u00a0<\/p>\n

\n Contact:<\/strong>
\n
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BIVI@redchip.com<\/a><\/p>\n

\n Chuck Padala<\/strong>
\n
Managing Director
LifeSci Advisors, LLC
chuck@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie\u2019s first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer\u2019s, Parkinson\u2019s, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation across clinical studies. He will also outline progress with BIV201, BioVie\u2019s late-stage orphan drug candidate for refractory ascites, a … <\/p>\n

Continue reading “Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-911529","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nJoin Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie\u2019s first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer\u2019s, Parkinson\u2019s, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation across clinical studies. He will also outline progress with BIV201, BioVie\u2019s late-stage orphan drug candidate for refractory ascites, a … Continue reading "Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T13:07:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9\",\"datePublished\":\"2025-11-19T13:07:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/\"},\"wordCount\":630,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/\",\"name\":\"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==\",\"datePublished\":\"2025-11-19T13:07:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/","og_locale":"en_US","og_type":"article","og_title":"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9 - Market Newsdesk","og_description":"CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie\u2019s first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer\u2019s, Parkinson\u2019s, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation across clinical studies. He will also outline progress with BIV201, BioVie\u2019s late-stage orphan drug candidate for refractory ascites, a … Continue reading \"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-19T13:07:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9","datePublished":"2025-11-19T13:07:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/"},"wordCount":630,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/","name":"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==","datePublished":"2025-11-19T13:07:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Nzg2MyM3MjcwMzA1IzUwMDA3OTY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/join-biovies-exclusive-live-investor-webinar-and-qa-session-on-december-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Join Biovie\u2019s Exclusive Live Investor Webinar and Q&A Session on December 9"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/911529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=911529"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/911529\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=911529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=911529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=911529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}